Evidence-based treatment of idiopathic generalized epilepsies with older antiepileptic drugs

Epilepsia

Volumn 46, Issue SUPPL. 9, 2005, Pages 149-153

  Hitiris, Nikolas ^a   Brodie, Martin J ^a  

^a WESTERN INFIRMARY   (United Kingdom)

Author keywords

Antiepileptic drugs; Clinical trials; Idiopathic generalized epilepsy

Indexed keywords

ACETAZOLAMIDE; ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CLONAZEPAM; ETHOSUXIMIDE; ETIRACETAM; MESUXIMIDE; PHENOBARBITAL; PHENYTOIN; PLACEBO; VALPROIC ACID;

ABSENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CHOICE; DRUG DOSE COMPARISON; DRUG INDICATION; DRUG MEGADOSE; EPILEPTIC STATE; EVIDENCE BASED MEDICINE; GENERALIZED EPILEPSY; HUMAN; IDIOPATHIC DISEASE; LOW DRUG DOSE; MONOTHERAPY; MYOCLONUS EPILEPSY; PRIORITY JOURNAL; REVIEW; TONIC CLONIC SEIZURE; TREATMENT OUTCOME; CLASSIFICATION; STATISTICS; SYNDROME;

ANTICONVULSANTS; CLINICAL TRIALS; EPILEPSY, GENERALIZED; HUMANS; SYNDROME; TREATMENT OUTCOME;

EID: 27944434101     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2005.00327.x     Document Type: Review

References (59)

1. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989;30:389-99.
2. Engel J Jr. A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: report of the ILAE task force on classification and terminology. Epilepsia 2001;42:796-803.
3. Parker AP, Agathonikou A, Robinson RO, et al. Inappropriate use of carbamazepine and vigabatrin in typical absence seizures. Dev Med Child Neurol 1998;40:517-9.
4. Zimmerman FT, Burgemeister BB. A new drug for petit mal epilepsy. Neurology 1958;8:769-75.
5. Heathfield KW, Jewesbury EC. Treatment of petit mal with ethosuximide. BMJ 1961;3:565-7.
6. Gordon N. Treatment of epilepsy with alpha-ethyl-alpha-methylsuccinimide (P.M. 671). Neurology 1961;11:266-8.
7. Livingston S, Pauli L, Najmabadi A. Ethosuximide in the treatment of epilepsy. Preliminary report. JAMA 1962;180:822-5.
8. O'Donohoe NV. Treatment of petit mal with ethosuximide. Dev Med Child Neurol 1964;91:498-501.
9. Weinstein AW, Allen RJ. Ethosuximide treatment of petit mal seizures. A study of 87 pediatric patients. Am J Dis Child 1966;111:63-7.
10. Blomquist HK, Zetterlund B. Evaluation of treatment in typical absence seizures. The roles of long-term EEG monitoring and ethosuximide. Acta Paediatr Scand 1985;74:409-15.
11. Browne TR, Dreifuss FE, Dyken PR, et al. Ethosuximide in the treatment of absence (petit mal) seizures. Neurology 1975;25:515-24.
12. Covanis A, Gupta AK, Jeavons PM. Sodium valproate: monotherapy and polytherapy. Epilepsia 1982;23:693-720.
13. Dulac O, Steru D, Rey E, et al. Sodium valproate monotherapy in childhood epilepsy. Arch Fr Pediatr 1982;39:347-52.
14. Henriksen O, Johannessen SI. Clinical and pharmacokinetic observations on sodium valproate - a 5-year follow-up study in 100 children with epilepsy. Acta Neurol Scand 1982;65:504-23.
15. Bourgeois B, Beaumanoir A, Blajev B, et al. Monotherapy with valproate in primary generalized epilepsies. Epilepsia 1987;28(suppl 2):8-11.
16. Braathen G, Theorell K, Persson A, et al. Valproate in the treatment of absence epilepsy in children: a study of dose-response relationships. Epilepsia 1988;29:548-52.
17. Villarreal HJ, Wilder BJ, Willmore LJ, et al. Effect of valproic acid on spike and wave discharges in patients with absence seizures. Neurology 1978;28:886-91.
18. Erenberg G, Rothner AD, Henry CE, et al. Valproic acid in the treatment of intractable absence seizures in children: a single-blind clinical and quantitative EEG study. Am J Dis Child 1982;136:526-9.
19. Suzuki M, Maruyama H, Ishibashi Y, et al. A double-blind comparative trial of sodium dipropylacetate and ethosuximide in epilepsy in children with pure petit mal seizures. Igaku No Ayumi 1972;82:470-88.
20. Sato S, White BG, Penry JK, Dreifuss FE et al. Valproic acid versus ethosuximide in the treatment of absence seizures. Neurology 1982;32:157-63.
21. Callaghan N, O'Hare J, O'Driscoll D, et al. Comparative study of ethosuximide and sodium valproate in the treatment of typical absence seizures (petit mal). Dev Med Child Neurol 1982;24:830-6.
22. Martinovic Z. Comparison of ethosuximide with sodium valproate. In:Parsonage M, Grant RH, Craig AG et al, eds. Advances in epileptology. XIVth Epilepsy International Symposium. New York: Raven Press, 1983:301-5.
23. Rowan AJ, Meijer JW, De Beer-Pawlikowski N, et al. Valproate-ethosuximide combination therapy for refractory absence seizures. Arch Neurol 1983;40:797-802.
24. Mattson RH, Cramer JA.Valproic acid and ethosuximide interaction. Ann Neurol 1980;7:583-4.
25. Pisani F, Narbone MC, Trunfio C, et al. Valproic acid-ethosuximide interaction: a pharmacokinetic study. Epilepsia 1984;25:229-33.
26. Chadwick DW, Cumming WJ, Livingstone I, et al. Acute intoxication with sodium valproate. Ann Neurol 1979;6:552-3.
27. Capocchi G, Balducci A, Cecconi M, et al. Valproate-induced epileptic tonic status. Seizure 1998;7:237-41.
28. Shahar E, Andraus J, Sagie-Lerman T, et al. Valproic acid therapy inducing absence status evolving into generalized seizures. Pediatr Neurol 2002;26:402-4.
29. Berkovic SF, Andermann F, Guberman A, et al. Valproate prevents the recurrence of absence status. Neurology 1989;39:1294-7.
30. Lombroso CT, Forxythe I. A long-term follow-up of acetazolamide (diamox) in the treatment of epilepsy. Epilepsia 1960;1:493-500.
31. Lombroso CT, Davidson DT Jr, Grossi-Bianchi ML. Further evaluation of acetazolamide (diamox) in treatment of epilepsy. JAMA 1956;160:268-72.
32. Ansell B, Clark E. Acetazolamide in the treatment of epilepsy. BMJ 1956;1:650-61.
33. Chao DH, Plumb L. Diamox in epilepsy. A critical review of 178 cases. J Pediatr 1961;58:211-8.
34. Mikkelsen B, Birket-Smith E, Bradt S, et al. Clonazepam in the treatment of epilepsy. A controlled clinical trial in simple absences, bilateral massive epileptic myoclonus, and atonic seizures. Arch Neurol 1976;33:322-5.
35. Sato S, Penry JK, Dreifuss FE. Clonazepam in the treatment of absence seizures: a double-blind clinical trial. Neurology 1977;27:371.
36. Canadian Clobazam Cooperative Group. Clobazam in treatment of refractory epilepsy: the Canadian experience. A retrospective study. Epilepsia 1991;32:407-16.
37. Wolf P, Inoue Y. Therapeutic response of absence seizures in patients of an epilepsy clinic for adolescents and adults. J Neurol 1984;231:225-9.
38. Grunewald RA, Panayiotopoulos CP. Juvenile myoclonic epilepsy. A review. Arch Neurol 1993;50:594-8.
39. Jeavons PM, Clark JE, Maheshwari MC. Treatment of generalized epilepsies of childhood and adolescence with sodium valproate ("epilim"). Dev Med Child Neurol 1977;19:9-25.
40. Asconape J, Penry JK. Some clinical and EEG aspects of benign juvenile myoclonic epilepsy. Epilepsia 1984;25:108-14.
41. Delgado-Escueta AV, Enrile-Bacsal F. Juvenile myoclonic epilepsy of Janz. Neurology 1984;34:285-94.
42. Calleja S, Salas-Puig J, Ribacoba R, et al. Evolution of juvenile myoclonic epilepsy treated from the outset with sodium valproate. Seizure 2001;10:424-7.
43. Christe W, Jacob R, Janz D. Juvenile myclonic epilepsy: response to valproate monotherapy in 27 previously untreated patients. Epilepsia 1995;36(suppl 3):65.
44. Panayiotopoulos CP, Obeid T, Tahan AR. Juvenile myoclonic epilepsy: a 5-year prospective study. Epilepsia 1994;35:285-96.
45. Karlovassitou-Koniari A, Alexiou D, Angelopoulos P, et al. Low dose sodium valproate in the treatment of juvenile myoclonic epilepsy. J Neurol 2002;249:396-9.
46. Panagariya A, Sureka RK, Sardana V. Juvenile myoclonic epilepsy - an experience from north western India. Acta Neurol Scand 2001;104:12-6.
47. Sundqvist A, Tomson T, Lundkvist B. Valproate as monotherapy for juvenile myoclonic epilepsy: dose-effect study. Ther Drug Monit 1998;20:149-57.
48. Faught E. Clinical trials for treatment of primary generalized epilepsies. Epilepsia 2003;44(suppl 7):44-50.
49. Obeid T, Panayiotopoulos CP. Clonazepam in juvenile myoclonic epilepsy. Epilepsia 1989;30:603-6.
50. Resor SR Jr, Resor LD. Chronic acetazolamide monotherapy in the treatment of juvenile myoclonic epilepsy. Neurology 1990;40:1677-81.
51. Hurst DL. Methsuximide therapy of juvenile myoclonic epilepsy. Seizure 1996;5:47-50.
52. Marson AG, Williamson PR, Clough H, et al. Carbamazepine versus valproate monotherapy for epilepsy: a meta-analysis. Epilepsia 2002;43:505-13.
53. Lerman-Sagie T, Lerman R. Phenobarbital still had a role in epilepsy treatment. Child Neurol 1999;14:820-1.
54. Wallace SJ. Myoclonus and epilepsy in childhood: a review of treatment with valproate, ethosuximide, lamotrigine and zonisamide. Epilepsy Res 1998;29:147-54.
55. Doose H. Myoclonic-astatic epilepsy. Epilepsy Res Suppl 1992;6:163-8.
56. Dravet C, Bureau M, Genton P. Benign myoclonic epilepsy of infancy: electroclinical symptomatology and differential diagnosis from the other types of generalized epilepsy of infancy. Epilepsy Res Suppl 1992;6:131-5.
57. Benbadis SR, Tatum WO, Gieron M. Idiopathic generalized epilepsy and choice of antiepileptic drugs. Neurology 2003;61:1793-5.
58. Posner EB, Mohamed K, Marson AG. Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. Cochrane Database Syst Rev 2003;3:CD003032.
59. Stokes T, Shaw EJ, Juarez-Garcia A, et al. Clinical guidelines and evidence review for the epilepsies: diagnosis and management in adults and children in primary and secondary care. London: Royal College of General Practitioners, 2004. Available at: http://www.nice.org.uk/pdf/ CG020fullguideline.pdf. (Accessed November 25, 2004).